research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
Search
for
Sort by
Research
30 / 1000+ results
research Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis
COVID-19 vaccination may be linked to alopecia areata, especially in young adults.
research Hair and nail adverse events during treatment with target therapies for metastatic melanoma
People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research Clinical analysis of 83 cases of severe alopecia areata
Combined therapy effectively improved severe alopecia areata in all patients after 6 months.
research Psychosomatic aspects of alopecia areata
The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.
research Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
research TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
research Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases
Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.
research COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research Efficacy and Safety of Oral Betamethasone Mini-Pulses in Moderate to Severe Alopecia Areata
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
research Epidemiology and burden of alopecia areata: a systematic review
Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
research Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients
Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research A clinical case of a patient with mucocutaneous and musculoskeletal manifestations after COVID-19 vaccination
A woman experienced severe symptoms, including hair loss, after a COVID-19 vaccine, suggesting a possible autoimmune reaction.
research Spontaneous complete resolution of alopecia totalis post SARS-CoV-2 infection
A woman's complete hair loss condition improved after recovering from COVID-19.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Alopecia universalis following human papillomavirus vaccine administration: a case report
A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Adverse effect profile with low-dose methotrexate therapy in patients suffering with rheumatic diseases
Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
research [A case of generalized komuragaeri disease (Satoyoshi disease) treated with glucocorticoid].
Glucocorticoid treatment improved symptoms in a girl with Satoyoshi disease.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.